Fenfluramine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Fenfluramine
- Fenfluramine: From an Unrecorded Original Indication to Proximal 16p11.2 Microdeletion Syndrome
Fenfluramine: From an Unrecorded Original Indication to Proximal 16p11.2 Microdeletion Syndrome
Summary
This evidence pack does not record fenfluramine’s original approved indication, and the drug is not currently marketed in Australia (0 ARTG entries). The TxGNN model’s top-ranked prediction links fenfluramine to proximal 16p11.2 microdeletion syndrome (score 99.93%), but this prediction is supported by zero clinical trials and zero literature — the evidence pack’s own rationale states there is no pharmacological plausibility for a serotonin-releasing agent in this rare chromosomal microdeletion disorder.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no licence or indication data recorded) |
| Predicted New Indication | Proximal 16p11.2 microdeletion syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Mechanism-of-action data for fenfluramine is not available in this evidence pack. This is the model’s single highest-scoring prediction among fenfluramine’s candidate indications, but the accompanying rationale explicitly states there is no known mechanistic link between fenfluramine and proximal 16p11.2 microdeletion syndrome, and no clinical trial or literature evidence exists for this pairing.
Proximal 16p11.2 microdeletion syndrome is a rare genomic microdeletion disorder affecting neurodevelopment. A serotonin-releasing agent has no established pharmacological rationale for intervening in this condition — the prediction should be read as a raw embedding-space signal from the model rather than a clinically motivated hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Fenfluramine has no ARTG entries and is not currently marketed in Australia.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction is evidence level L5 (model prediction only) with no supporting clinical trials or literature, and the evidence pack’s own mechanistic assessment finds no pharmacological plausibility. Combined with a blocking data gap on Product Information warnings/contraindications and a high-severity gap on mechanism of action, this candidate does not meet the bar for further evaluation as currently scored.
To proceed, the following is needed:
- TGA-approved Product Information (warnings, contraindications) — currently a blocking data gap (DG001)
- Mechanism-of-action data via DrugBank — currently a high-severity data gap (DG002)
- Documented original indication history for fenfluramine, to establish a proper baseline for comparison
- If repurposing is still of interest, other candidates in this pack — e.g. fatty liver disease (rank 9, evidence level L4, decision stage S1, indirect weight-loss-mediated mechanism) — warrant a separate, dedicated evaluation rather than the rank-1 signal used here
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.